BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

There is severe disruption at Bristol Airport on Saturday, January 4 as flight operations have been suspended due to poor ...

The biggest change to Bristol is coming - the biggest since the aftermath of the Second World War - and most people don’t ...

Most of the UK is covered by Met Office weather warnings during Sunday as the cold start to the new year continues.

The grade of financial health, once a figure tucked away on loan applications, has become an everyday obsession for more ...

Yoran, 54, joined Tenable as CEO in 2016 and was credited with steering the company's growth, including its 2018 initial public offering. The company said it would continue to operate under the ...

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...

Federal Reserve Bank of San Francisco President Mary Daly and Federal Reserve Board Governor Adriana Kugler speak as they attend the American Economics Association's annual conference, in San ...